A comparison of fetal-loss reports in the Vaccine Adverse Event Reporting System (VAERS) during three consecutive influenza seasons shows there was a synergistic toxicity causing spontaneous abortions (SAB) and stiillbirths (SB) following the Center for Disease Control (CDC) recommendations of pandemic and influenza vaccines administered to pregnant women.

An overwhelming majority of pregnant women who visit the doctor's office are now refusing the flu vaccine over fears it will harm their fetus and their fears are now scientifically justified. More than 90% of all expecting mothers will now say no to the flu vaccine due to fear of miscarriage and delivery of toxic byproducts to their unborn child.

In 2011, Dr. Alessandro Bertoucci who analyzed the practices of 256 physicians treating more than 600,000 patients, reported that a staggering 91% of pregnant women are declining influenza vaccines due to fears of miscarriage and suspected toxins in the vaccine itself.

A study published last year in the Human and Experimental Toxicology journal found a direct statistical correlation between higher vaccine doses and infant mortality rates. It was a confirmation that many anti-vaccine advocates have long awaited and further establishes and adds to preliminary evidence that vaccinations are toxic poisons having no place in the human body.

The infant mortality rate (IMR) is one of the most important indicators of the socio-economic well-being and public health conditions of a country. The US childhood immunization schedule specifies 26 vaccine doses for infants aged less than 1 year--the most in the world--yet 33 nations have lower IMRs. Australia and Canada are a close 2nd and 3rd respectively with 24 vaccine doses.

Some countries have IMRs that are less than half the US rate: Singapore, Sweden, and Japan are examples. According to the Centers for Disease Control and Prevention (CDC), "The relative position of the United States in comparison to countries with the lowest infant mortality rates appears to be worsening."

Goldman's most recent study Comparison of VAERS fetal-loss reports during three consecutive influenza seasons successfully correlated fetal toxicity resulting from the administration of both the pandemic (A-H1N1) and seasonal influenza vaccines during the 2009/10 season.

Since 1997, the Advisory Committee on Immunization Practices (ACIP) has recommended the routine vaccination of pregnant women with trivalent inactivated influenza vaccine (TIV) after the first trimester of pregnancy. This recommendation was expanded in 2004 to include all trimesters of pregnancy.

All previously published studies of pregnant women who were administered TIV have reported this vaccine as safe during all stages of pregnancy.

Frequently cited peer-reviewed reports on the safety of influenza vaccination during pregnancy do not reveal any adverse outcomes among women. Many of these studies, used “no Thimerosal” influenza vaccines, had insufficient statistical power to adequately detect and assess complications due to the small sample size.

In another follow-up safety study (conducted among 2,291 pregnant women) cited by ACIP did not find increased childhood mortality associated with exposure to TIV in pregnancy. However, fetallosses were not included in the analysis as found in critical assessments of the study.

The safety and effectiveness of the pandemic (monovalent influenza) A-H1N1 vaccine had not been previously established in pregnant women. Nor was the combination of two different influenza vaccines ever tested in pregnant women. The A-H1N1 vaccine inserts from the various manufacturers contained this caution: “It is also not known whether these vaccines can cause fetal harm when administered to pregnant women or can affect reproduction capacity.”

In October 2010, Moro et al summarized that during 19 influenza seasons (1990/91 through 2008/09) there were a total of 17 spontaneous abortion (SAB) and 6 stillbirth (SB) reports following TIV in VAERS database.

An independent survey was conducted by the National Coalition of Organized Women (NCOW) via the Internet to serve as a second surveillance source for pregnant women suffering A-H1N1 fetal loss during the two-vaccine 2009/10 influenza season. Eileen Dannemann, director of NCOW, oversaw this study and the data collected are summarized in the Results section. In response to a public service announcement delivered via several websites on the Internet, respondents contacted one of two study coordinators via phone or e-mail address. The respondents provided relevant details including (a) type of influenza vaccine received, (b) date of vaccination, (c) type of vaccine, (d) date of onset of symptom(s), (e) date of spontaneous abortion or miscarriage, (f) geographic location, (g) whether or not the adverse event was reported to VAERS, and (h) other miscellaneous comments.

Results from Goldman's study shows that although there was an approximate 4-fold (43%/11.3%) increase in the percentage of pregnant women vaccinated in 2009/10 compared to 2008/09, there was a 43.5-fold increase in fetal-loss reports--from 4 in 2008/09 to 174 in 2009/10.

Based on respondents’ comments to the NCOW survey in the 2009/10 season, it is likely that the ascertainment-corrected rate of 535 fetal losses per million pregnant women vaccinated represents a significant underestimate during the two-vaccine 2009/10 influenza season since healthcare professionals explained to patients “the benefits of influenza vaccination outweighed the risks.” Medical literature reporting the mean rate of “1.9 fetal losses per million pregnant women vaccinated” for the previous 19 single-vaccine influenza seasons based on counts of VAERS reports that were not adjusted for under-ascertainment, likely contributed to this perception of safety. Because both patient and healthcare professionals relied on a historical profile that was incomplete with respect to assessing fetal-demise reporting, a possible link to fetal demise following administration of influenza vaccine(s) during 2009/10 was rarely contemplated or was considered highly unlikely and thus, more often than not, not reported.

When one or more Thimerosal-containing vaccines, including some formulations of the seasonal TIV and pandemic monovalent A-H1N1 vaccines are administered to a pregnant woman, the fetus is also indirectly exposed to mercury.

The linkage between Thimerosal and neurodevelopmental disorders is a concern because several studies have shown that children with autistic spectrum disorders (ASDs) have higher levels of mercury body burden than typically developing children. In addition, there is a positive correlation between mercury body burden and severity of ASD symptoms. Direct measurement of injury in the brains of children with ASD reinforce this finding; there is a significant dose-dependent positive correlation between oxidative stress markers (evidence of brain injury) and mercury levels in the brains of children with ASD.

The amount of mercury that accumulates in any given fetus and the severity of its impact depend upon several factors in addition to the maternal mercury exposure due to injected Thimerosal-containing inactivated-influenza vaccines. Dental amalgams in pregnant woman contribute to increased mercury burden in the developing fetus and newborn. Also, the maternal-fetal genetic background can modulate fetal exposure to mercury; thus, certain gene variants influence mercury toxicokinetics causing the variable susceptibility that is observed with respect to mercury toxicity. This variation in genetic susceptibility, combined with factors of diet and antibiotic use, can synergistically enhance mercury toxicity and effectively preclude establishment of a safe mercury dosing level for all individuals.

Moreover, the 0.1 mcg/kg-day reference dose that the Environmental Protection Agency (EPA) established as safe based on oral ingestion of mercury is not applicable for injected Thimerosal via vaccination since injection bypasses the absorption protection provided by the gastrointestinal system intestines (which is also apparently dependent on the manner in which the fish or other mercury-containing food is prepared), thereby delivering more of the toxic dose of mercury administered into the body.

Thus, it is biologically plausible that during the two-vaccine 2009/10 influenza season, when pregnant women were administered two Thimerosal-containing influenza vaccines each delivering 50 mcg of Thimerosal (or 25 mcg of mercury per dose), the fetus’ mercury dose exceeded the EPAs reference (oral) dose for oral exposure of (0.1 mcg of mercury/kg-day). This over-exposure could be a significant contributing factor to some of the reported SABs and SBs. Moreover, the mercury in injected Thimerosal-containing vaccine doses has been found to preferentially bioaccumulate in the fetal tissues.

The study concluded that the concomitant administration of the seasonal influenza and pandemic A-H1N1 vaccines during 2009/10, suggests a synergistic toxicity and a statistically significant higher rate of fetal loss reporting relative to the single-dose seasons.

The VAERS rates of 6.8 and 12.6 fetal-loss reports per million women vaccinated for those single-vaccine seasons may provide healthcare professionals with a sense that influenza vaccines administered during pregnancy are relatively safe, when, in reality, these rates merely reflect the low level of case ascertainment associated with VAERS and thus, grossly underestimate the true rates encountered in the U.S. population. Just because a single vaccine has been tested and considered safe, does not imply there will not be a synergistic fetal toxicity effect associated with the administration of two or more Thimerosal-containing vaccines to a pregnant woman and/or a synergistic toxicity effect from the combination of the biologically active components contained in concomitantly administered vaccines.

In addition, because of the order of magnitude increase in fetal-loss report rates, from 6.8 fetal-loss reports per million pregnant woman vaccinated in the 1-dose 2008/09 season to 77.8 in the 2-dose 2009/10 season, further long-term studies are needed to assess adverse outcomes in the surviving children. Additional research concerning the risk factors associated with the potential synergistic toxicity associated with the administration of Thimerosal-containing vaccines is warranted and the exposure-effect association should be verified in further toxicological and case-control studies.